ASX ANNOUNCEMENT
1 FEBRUARY 2021

FORMER JUNO EXECUTIVE CINDY ELKINS JOINS CHIMERIC AS NON-EXECUTIVE DIRECTOR

HIGHLIGHTS

- Ms Elkins brings more than 30 years experience in the biotech and high tech industries, with roles at Juno Therapeutics, Genentech/Roche, and Ariba
- She created Juno Therapeutics global CAR T patient experience, connecting patients with their personalised medicine through world leading service and technology
- Juno was acquired for $11 billion by Celgene in 2018, which in turn was acquired by Bristol-Myers-Squibb for $74 billion a year later, the third largest biotech acquisition ever
- Ms Elkins' expertise in business leadership and technology will assist in the commercialisation of Chimeric's CLTX-CAR T asset
- Other directorships include Weight Watchers and The Foundation for Art & Healing

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), a drug development company focused on novel CAR T cell therapies for solid tumors, is pleased to announce the appointment of Cindy Elkins as Non-Executive Director.

Elkins' experience includes her role as Executive Vice President and Chief Information Officer at Juno Therapeutics, one of the pioneers in CAR T technology focused on blood cancers. Her role evolved into Head of Global CAR T Patient Experience, responsible for connecting patients with their personalised medicine through world leading service and technology. Juno was acquired by major global pharmaceutical company Celgene Corporation in 2018 for $11 billion. Celgene was then acquired by Bristol-Myers Squibb in 2019 for $74 billion, the third largest pharmaceutical company acquisition ever.

Prior to Juno, Elkins was Vice-President of Pharma Informatics at Genentech/Roche, where she was instrumental in ensuring all technology systems/processes were ready as soon as the FDA approved new medicines such as Zelboraf®, Gazyva®, Cotellic® and Tecentriq®. In this role she led a team of over 900 people in 12 countries across the Americas. Prior to Genentech, she was VP and General Manager at Ariba, where she created the largest transacting B2B eCommerce network in the world that now transacts over $3.5T annually.

Ms Elkins sat on the board of directors and audit committee for global wellness and weight loss company Weight Watchers for five years and is currently board chair of The Foundation for Art & Healing whose signature initiative is The UnLonely Project.

Chimeric's Executive Chairman, Paul Hopper said: "Cindy is an outstanding addition to Chimeric's board of directors. Her long and successful career with renowned pharma businesses, specifically in the CAR T sector, will prove invaluable as we look to develop and commercialise our CLTX-CAR T asset."

Chimeric's CLTX-CAR T therapy, which uses a peptide derived from scorpion toxin to direct T cells to target glioblastoma (GBM), is currently being used in a Phase 1 clinical trial at City of Hope to treat GBM.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

LEVEL 3, 62 LYGON STREET
CARLTON VIC 3053, AUSTRALIA

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is developing ground-breaking CAR T cell therapies for solid tumors based on scientific research conducted by leading US CAR T experts at the City of Hope (COH) Cancer Centre in Los Angeles. Its CLTX-CAR T technology incorporates chlorotoxin (CLTX), a peptide derived from scorpion toxin, as a novel CAR tumor recognition domain. This domain extends the range of CAR T cell targeting in solid tumors.

Potent antitumor activity against glioblastoma (GBM) has been established in preclinical models. Currently undergoing Phase 1 clinical trials in GBM at COH, CLTX-CAR T has significant drug administration benefits since it can be delivered during an outpatient visit.

CLTX-CAR T cells differ from other GBM-targeting immunotherapies by its specific and broad recognition of patient tumors and of the majority of cells within these tumors. CLTX-CAR T cells target GBM through recognition of a receptor complex composed of membrane-bound matrix metalloprotease 2 (MMP2) and involving the chloride channel CLC3.

CLTX-CAR T cells do not exhibit off-tumor recognition of normal human or murine cells/tissues in preclinical models, consistent with the documented safety of administering other CLTX-containing therapeutic agents in humans.

The CLTX peptide has also demonstrated safety and specificity in clinical testing as a radiotherapy delivery conjugate and as an imaging agent in fluorescence-guided surgery for recurrent/refractory GBM.

CONTACT

Investors
Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au